drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
Genetically engineered T cells (autologous or donor-derived) modified to express a chimeric antigen receptor targeting CD33 (Siglec-3) on AML cells. Following IV infusion, the CAR provides CD3ζ signaling with co-stimulation to drive antigen-dependent T-cell activation and HLA-independent cytotoxicity (granule release and cytokines) against CD33+ AML blasts and normal myeloid progenitors/monocytes.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous or donor-derived T cells engineered to express a CD33-specific chimeric antigen receptor; CAR engagement of CD33 on AML cells triggers CD3ζ-based signaling with co-stimulation, leading to antigen-dependent, HLA-independent T-cell activation and cytotoxic killing (perforin/granzyme release and cytokines) of CD33+ blasts and normal myeloid progenitors.
drug_name
FL-33 CD33-directed CAR T-cell therapy
nct_id_drug_ref
NCT06326021